1. Home
  2. EXPI vs AGIO Comparison

EXPI vs AGIO Comparison

Compare EXPI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo eXp World Holdings Inc.

EXPI

eXp World Holdings Inc.

HOLD

Current Price

$6.90

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$29.25

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXPI
AGIO
Founded
2008
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2010
2013

Fundamental Metrics

Financial Performance
Metric
EXPI
AGIO
Price
$6.90
$29.25
Analyst Decision
Strong Buy
Buy
Analyst Count
1
8
Target Price
$11.50
$36.63
AVG Volume (30 Days)
998.8K
761.1K
Earning Date
05-27-2026
05-15-2026
Dividend Yield
2.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$500,147,681.00
$43,011,000.00
Revenue This Year
$6.93
$103.08
Revenue Next Year
$7.02
$126.67
P/E Ratio
N/A
N/A
Revenue Growth
220.39
N/A
52 Week Low
$6.91
$22.24
52 Week High
$12.23
$46.00

Technical Indicators

Market Signals
Indicator
EXPI
AGIO
Relative Strength Index (RSI) 21.52 53.62
Support Level N/A $26.40
Resistance Level $11.36 $29.49
Average True Range (ATR) 0.34 1.24
MACD -0.03 0.21
Stochastic Oscillator 8.66 64.33

Price Performance

Historical Comparison
EXPI
AGIO

About EXPI eXp World Holdings Inc.

eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: